A platelets-inspired nanoparticle to restore bleeding control for people on antiplatelet drugs
Official title: A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet Agents
Funded at Haima Therapeutics, LLC · NIH-11542792 · Data updated 2026-11-12
A new, platelet-inspired nanoparticle therapy aims to restore normal blood clotting in people taking antiplatelet medicines who are at risk of dangerous bleeding.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Haima Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 15, 2025 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $50,000 |
| NIH project number | 3R44HL180258-02S1 |
| Project ID | NIH-11542792 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults on antiplatelet therapy who are at risk of significant bleeding or who require urgent surgical interventions.
✕Less likely to help
People not on antiplatelet therapy or without bleeding risk related to antiplatelet drugs may not benefit.
What this research studies
If you take antiplatelet drugs like clopidogrel or ticagrelor, you can bleed more easily, especially during surgery or after injury. This project develops a novel, platelet-inspired nanotechnology intended to quickly restore hemostasis in those patients. It focuses on a donor-independent approach that could work alongside current treatments when bleeding risk is high and traditional reversal agents are not effective. The work is early-stage and designed to set the stage for future clinical testing in humans. The goal is to reduce bleeding complications and the need for transfusions by providing a fast, ready-to-use hemostatic option.
Why it matters
Potential benefit: If successful, this therapy could reduce bleeding complications and hospital stays for patients on antiplatelet medicines.
How similar studies have gone: Previous approaches struggle with donor dependence and limited efficacy; this project explores a novel, donor-independent strategy that is still early in development.
Where this research is happening
-
Haima Therapeutics, LLC
Cleveland, United States Active
Researchers
- Principal investigator: Sekhon, Ujjal Didar Singh — Haima Therapeutics, LLC
- Study coordinator: Sekhon, Ujjal Didar Singh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.